Replies to post #159052 on Biotech Values

[DewDiligence]

NVS will almost certainly increase the rebates on Gilenya to match the US AWP of Tecfidera.

The injectables, Copaxone, Rebif and Avonex will start to wither away once the safety parameters are met.

Such a comment shows a lack of understanding of the MS market, where patients switch drugs infreqeuntly.